UPDATE: Deutsche Bank Raises PT on Medicis Pharmaceutical to $36 (MRX)

Deutsche Bank is out with its report today on Medicis Pharmaceutical MRX, raising its price target from $35 to $36. In a note to clients, Deutsche Bank writes, "We are updating our model based on trends for currently marketed products and the discontinuation of LipoSonix and Plexion. We are modestly lowering our EPS ests from $2.53 to $2.51 in 2011, $2.85 to $2.80 in 2012, and $3.19 to $3.14 in 2013. Our new 12-month PT is $36, based on 13x our new 2012 EPS est. Potential risks to our PT being achieved principally relate to the aesthetic franchises and Rx trends for Solodyn and Ziana." Deutsche Bank maintains Buy on MRX. At the time of posting, shares of MRX were trading pre-market at $30.35, up 17.54% from Friday's close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsDeutsche BankHealth CareMedicis PharmaceuticalPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!